Sep 12, 2018 7:00am EDT Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)
Sep 04, 2018 7:00am EDT Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year
Aug 31, 2018 7:00am EDT Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update
Aug 29, 2018 7:00am EDT Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aug 21, 2018 7:00am EDT Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis
Aug 07, 2018 9:14am EDT Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China
Aug 06, 2018 5:54am EDT Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical
Jul 17, 2018 7:00am EDT Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug
Jul 02, 2018 7:00am EDT Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer
